Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT04313881
Other study ID # 5F9009
Secondary ID 2020-004287-26
Status Terminated
Phase Phase 3
First received
Last updated
Start date September 9, 2020
Est. completion date September 13, 2023

Study information

Verified date March 2024
Source Gilead Sciences
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary objective of this study is to evaluate the efficacy of magrolimab in combination with azacitidine compared to that of azacitidine plus placebo in previously untreated participants with intermediate/high/very high risk myelodysplastic syndrome (MDS) by Revised International Prognostic Scoring System (IPSS-R) as measured by complete remission (CR) and overall survival (OS).


Recruitment information / eligibility

Status Terminated
Enrollment 539
Est. completion date September 13, 2023
Est. primary completion date September 13, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Key Inclusion Criteria: - Participants with Myelodysplastic Syndrome (MDS) defined according to World Health Organization classification, with Revised International Prognostic Scoring System (IPSS-R) prognostic risk category of intermediate, high, or very high risk. - Adequate performance status and hematological, liver, and kidney function. Key Exclusion Criteria: - Immediate eligibility for allogenic stem cell transplant (SCT), as determined by the investigator, with an available donor. - Prior treatment with Cluster of Differentiation (CD) 47 or Signal-regulatory protein alpha (SIRPa)-targeting agents. - Any prior antileukemic therapy for treatment of intermediate, high, very high risk MDS per IPSS-R. - Second malignancy, except treated basal cell or localized squamous skin carcinomas, localized prostate cancer, or other malignancies for which participants are not on active anticancer therapies and have had no evidence of active malignancy for at least = 1 year. - Contraindications to azacitidine. - Clinical suspicion of active central nervous system (CNS) involvement by MDS. - Known active or chronic hepatitis B or C infection or human immunodeficiency virus in medical history . - Active hepatitis B virus and/or active hepatitis C virus, and/or HIV following testing at screening. - Pregnancy or active breastfeeding. Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Magrolimab
Administered intravenously
Azacitidine
Administered either subcutaneously (SC) or intravenously (IV) according to region-specific drug labeling
Placebo
Placebo to match magrolimab administered intravenously

Locations

Country Name City State
Australia Royal Adelaide Hospital Adelaide South Australia
Australia Flinders Medical Center Bedford Park South Australia
Australia Eastern Health Box Hill Victoria
Australia Monash Medical Centre Clayton Victoria
Australia Peninsula Private Hospital Frankston Victoria
Australia Barwon Health, University Hospital Geelong Geelong Victoria
Australia Gosford Hospital Gosford New South Wales
Australia Royal Hobart Hospital Hobart Tasmania
Australia Cabrini Hospital Malvern Malvern Victoria
Australia The Alfred Hospital Melbourne Victoria
Australia Sir Charles Gairdner Hospital Nedlands Western Australia
Australia Royal Melbourne Hospital Parkville Victoria
Australia Prince of Wales Hospital Randwick New South Wales
Australia Icon Cancer Foundation South Brisbane Queensland
Australia Royal North Shore Hospital St Leonards New South Wales
Australia Westmead Hospital Westmead New South Wales
Austria Uniklinikum Salzburg Salzburg
Austria Hanusch kranhenkaus, 3. Medizinische Abteilung Vienna
Belgium ZNA Middelheim Antwerpen
Belgium Cliniques Universitaires Saint-Luc Brussels
Belgium ULB Hopital Erasme Brussels
Belgium UZ Brussel Brussels
Belgium UZ Leuven Leuven
Belgium AZ Turnhout, Campus St. Elisabeth Turnhout
Belgium Chu Ucl Namur Site Godinne Yvoir-Godinne
Canada Tom Baker Cancer Centre Calgary
Canada QEII Health Sciences Centre Halifax
Canada Eastern Regional Health Authority St. John's
Canada University Health Network Toronto
Czechia Fakultni nemocnice Olomouc, Hemato-onkologicka klinika Olomouc
Czechia Fakultni nemocnice Ostrava, Klinika hemato-onkologicka Ostrava
Finland Helsinki University Central Hospital Helsinki
Finland Oulu University Hospital Oulu
France CHU Amiens-Picardie Amiens Cedex 1
France Hopital Henri Mondor Creteil
France CHU de Grenoble Alpes La Tronche
France Institut Paoli Calmettes Marseille
France Hopital Saint Eloi Montpellier
France CHU de Nantes Nantes
France CHU de Nice-l Archet Nice
France Hopital Saint Louis Paris
France Institut Gustave Roussy Paris
France Hopital Haut-Leveque Pessac Cedex
France Centre Hospitalier Lyon Sud Pierre Benite
France CHU de Poitiers - Hopital de la Miletrie Poitiers
France CHU de Rennes- Hopital Pontchaillou Rennes Cedex 9
Germany Universitatsmedizin der Johannes Gutenberg Universitat Mainz, III. Medizinische Klinik und Poliklinik Braunschweig
Germany Universitatsklinikum Carl Gustav Carus Dresden
Germany Marien hospital, klinik fur onkologie, hamatologie und palliavmedizin Duesseldorf
Germany Universitatsklinikum Essen Essen
Germany Universitat Leipzig Leipzig
Germany Robert-Bosch-Krankenhaus, GmBH, Hamatologie, Onkologie und Palliativmedizin Stuttgart
Hong Kong Hong Kong Sanatorium & Hospital Hong Kong
Hong Kong Princess Margaret Hospital Hong Kong
Hong Kong Queen Mary Hospital Hong Kong
Hong Kong The Chinese University of Hong Kong, Prince of Wales Hospital Hong Kong
Hong Kong Tuen Mun Hospital Hong Kong
Hungary Semmelweis Egyetem Belgyógyászati és Hematológiai Kilnika Budapest
Hungary Debreceni Egyetem Klinikai Központ Debrecen
Hungary Petz Aladar Egyetemi Oktato Korhaz II. Belgyogyaszat - Hematologial Osztaly Gyor
Hungary Kaposi Mor Teaching Hospital Kaposvar
Hungary Bács-Kiskun Megyei Kórház Kecskemet
Hungary SzSzB Megyei Korhazak es Egyetemi Oktatokorhaz Nyiregyhaza
Hungary University of Pecs Pecs
Hungary Szent Borbála Hospital Tatabanya
Italy SC Ematologica- Azienda Ospedaliera Nazionale SS. Antonio e Biagio e C. Arrigo Alessandria
Italy U.O Ematologica- ASST degli Spedali Civili di Brescia Brescia
Italy Azienda Ospedaliero-Universitaria Careggi Firenze
Italy U.O.C Ematologia - Dipartimento di Medicina Interna, Fondazione IRCCS Ca'Granda Ospedale Maggiore Policlinico Milan
Italy U.O di Ematologia, Ospedale San Gerardo- ASST Monza Monza
Italy S. C. Ematologia Azienda Ospedaliero - Universitaria Maggiore Della Carita Novara
Italy Azienda Ospedaliera Ospedali Riuniti Marche Nord Pesaro
Italy SC di Oncoematologia - Azienda Ospedaliera Santa Maria Terni
Italy SC Ematologica, ASST Sette Laghi, Ospedale di Circolo e Fondazione Macchi Varese
Netherlands University Medical Center Groningen Groningen
Netherlands Medisch Centrum Leeuwarden Leeuwarden
New Zealand Christchurch Hospital Christchurch
New Zealand Southern District Health Board Dunedin
New Zealand Auckland City Hospital Grafton
New Zealand Waikato Hospital Hamilton
New Zealand Midcentral District Health Board Palmerston North
Norway Haukeland Universitetssjukehus, seksjon for blodsjukdommar- klinisk studieteam Bergen
Norway Akershus University Hospital Loerenskog
Norway Oslo University Hospital Oslo
Norway Stavanger universitetssjukehus Stavanger
Poland Samodzielny Publiczny Zaklad Opieki Zdrowotnej Szpital Uniwersytecki w Krakowie, Oddzial Kliniczny Hematologii Krakow
Poland Centrum Onkologii Ziemi Lubelskiej im. sw. Jana z Dukli Lublin
Poland Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wroclawiu Wroclaw
Portugal Centro Clinico Academico de Braga, Hospital de Braga, E.P.E Braga
Portugal Champalimaud Foundation Lisbon
Portugal Hospital da Luz Lisbon
Portugal Centro Hospitalar Universitario Sao Joao. E.P.E Porto
Portugal Centro Hospitalar Vila Nova de Gaia/Espinho Porto
Portugal Instituto Portugues de Oncologia do Porto Francisco Gentil, EPE Porto
Spain Area Sanitaria de Santiago de Compostela y Barbanza. Complejo Hospitalario Universitario de SantiagoD A Coruña
Spain OSI Araba, Hospital Universitario de Alava, Hospital Txagorritxu Alava
Spain Hospital del Mar Barcelona
Spain Hospital Universitari Vall D'Hebron Barcelona
Spain Institut Catala d'Oncologia Girona Girona
Spain Institut Catala d'Oncologia, Hospital Duran i Reynals L´Hospitalet de Llobregat
Spain Hospital Universitario Fundacion Jimenez Diaz Madrid
Spain Hospital Universitario La Paz, Edificio General, 6 Planta. Despacho de Hematologia Madrid
Spain Hospital Universitario Quironsalud Madrid. Servico de Hematologica y Hemoterapia Madrid
Spain MD Anderson Cancer Center Madrid Madrid
Spain Hospital Regional Universitario de Malaga Malaga
Spain Centro Hospitalar Universitario Sao Joao Pamplona
Spain Complejo Asistencial Universitario de Salamanca- Hospital Clinico Universitario de Salamanca Salamanca
Spain Hospital Universitario Virgen del Rocio Sevilla
Spain Hospital Clinico Universitario de Valencia Valencia
Switzerland Istituto Oncologico Della Svizzera Italiana- IOSI, EOC, Clinica di Ematologia Bellinzona
Switzerland University of Bern Bern
Switzerland Universitaetsspital Zurich - Klinik fur Medizinische Onkologie und Hematologie Zurich
Turkey Ankara Universitesi Tip Fakultesi Cebeci Hastanesi Ankara
Turkey Gazi Universitesi Tip Fakultesi Ankara
Turkey Hematoloji Bilim Dali, Yenimahalle Ankara
Turkey Dokuz Eylul Universitesi Tip Fakultesi Onkoloji Enstitusu Inciralt
Turkey Mersin University Medical Mersin
Turkey Tekirdag Namik Kemal Universitesi Tip Fakultesi Tekirdag
United Kingdom University Hospitals Birmingham NHS Foundation Trust Birmingham
United Kingdom United Lincolnshire Hospital NHS Trust Boston
United Kingdom Kent and Canterbury Hospital- East Kent Hospitals University NHS Foundation Trust Canterbury
United Kingdom Oxford University Hospitals NHS Foundation Trust Oxford
United States University of Michigan Medical School Ann Arbor Michigan
United States Winship Cancer Institute Atlanta Georgia
United States Johns Hopkins Medicine - The Sidney Kimmel Comprehensive Cancer Center Baltimore Maryland
United States University of Maryland, Greenebaum Comprehensive Cancer Center Baltimore Maryland
United States University of Alabama Birmingham Birmingham Alabama
United States Beth Israel Deaconess Medical Center Boston Massachusetts
United States Dana Farber Cancer Institute (DFCI) Boston Massachusetts
United States Massachusetts General Hospital Boston Massachusetts
United States Roswell Park Cancer Institute Buffalo New York
United States University of North Carolina at Chapel Hill Chapel Hill North Carolina
United States Northwestern Memorial Hospital Chicago Illinois
United States The University of Chicago Medical Center Chicago Illinois
United States The Ohio State University Wexner Medical Center / James Cancer Hospital Columbus Ohio
United States Texas Oncology - Baylor Charles A. Simmons Cancer Center Dallas Texas
United States UT Southwestern Medical Center Dallas Texas
United States City of Hope Duarte California
United States DUHS Duke Cancer Center Durham North Carolina
United States University of Kansas Clinical Research Center Fairway Kansas
United States Prisma Health Cancer Center Greenville South Carolina
United States Baylor College of Medicine Houston Texas
United States The University of Texas MD Anderson Cancer Center Houston Texas
United States Mid America Division, Inc. Kansas City Missouri
United States UC San Diego Moores Cancer Center La Jolla California
United States University of Arkansas for Medical Sciences IRB Little Rock Arkansas
United States UCLA Ronald Reagan Medical Center Los Angeles California
United States University of Miami Hospital and Clinics / Sylvester Comprehensive Cancer Center Miami Florida
United States Froedtert Hospital & the Medical College of Wisconsin Milwaukee Wisconsin
United States University of Minnesota Medical Center, Fairview Minneapolis Minnesota
United States Tennessee Oncology, PLLC Nashville Tennessee
United States Tulane Medical Center New Orleans Louisiana
United States Columbia University Medical Center - Herbert Irving Pavilion New York New York
United States Memorial Sloan Kettering Cancer Center New York New York
United States Mount Sinai Health System New York New York
United States Weill Cornell Medicine-New York Presbyterian Hospital New York New York
United States University of Oklahoma Health Sciences Center Oklahoma City Oklahoma
United States UC Irvine Health Orange California
United States Stanford Cancer Institute Palo Alto California
United States Fox Chase Cancer Center Philadelphia Pennsylvania
United States Hospital of the University of Pennsylvania Philadelphia Pennsylvania
United States Thomas Jefferson University, Sidney Kimmel Cancer Center; Clinical Research Organization Philadelphia Pennsylvania
United States Oregon Health & Science University Pharmacy Services Portland Oregon
United States University of California, Davis Comprehensive Cancer Center Sacramento California
United States Washington University School of Medicine - Siteman Cancer Center Saint Louis Missouri
United States Huntsman Cancer Institute/University of Utah Salt Lake City Utah
United States Seattle Cancer Care Alliance Seattle Washington
United States Swedish Cancer Institute Seattle Washington
United States Moffitt Cancer Center Tampa Florida

Sponsors (1)

Lead Sponsor Collaborator
Gilead Sciences

Countries where clinical trial is conducted

United States,  Australia,  Austria,  Belgium,  Canada,  Czechia,  Finland,  France,  Germany,  Hong Kong,  Hungary,  Italy,  Netherlands,  New Zealand,  Norway,  Poland,  Portugal,  Spain,  Switzerland,  Turkey,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of Participants With Complete Remission (CR) The percentage of participants (CR rate) are participants who reach morphologic CR (morphological blast of = 5% and recovery of absolute neutrophil count (ANC), platelets, and hemoglobin from complete blood counts as well as peripheral blast) based on Investigator-assessed International Working Group (IWG) myelodysplastic syndrome (MDS) criteria on or prior to initiation of any new anticancer therapy, including stem cell therapy (SCT). Percentages were rounded off. From randomization up to 31.01 months
Primary Overall Survival (OS) OS is defined as the number of months measured from the date of randomization to the date of death from any cause. Kaplan Meier (KM) estimates were used for analysis. From randomization up to 32.62 months
Secondary Duration of CR (DOCR) DOCR=Time from first CR date to the first date of relapse, disease progression (PD) or death, whichever occurs earlier. PD is defined as: <5% blasts: =50 increase in blasts to >5% blasts,5%-10% blasts: =50% increase in blasts to >10% blasts, 10%-20% blasts: =50% increase in blasts to >20% blasts,20%-30% blasts: =50% increase in blasts to >30% blasts, any of the following: at least 50% decrement from maximum remission/response in granulocytes or platelets. Reduction in Hgb by =2 g/dL / Transfusion dependence. Relapse is defined as return to pretreatment bone marrow blast percentage / decrement of = 50% from maximum remission/response levels in granulocytes or platelets/ reduction in Hgb concentration by = 1.5 g/dL or transfusion dependence. CR is defined in outcome measure 1. KM estimates were used for analysis. From randomization up to 31.01 months
Secondary Objective Response Rate (ORR) ORR is defined as the percentage of participants who reach objective response including CR, partial remission (PR), marrow CR or hematological improvement prior to initiation of any new anticancer therapy including SCT for MDS per IWG 2006 criteria per investigator's evaluation. CR is defined in outcome measure 1.
PR is defined as all CR criteria if abnormal before treatment except, one marrow blasts decreased by = 50% over pretreatment but still > 5% cellularity and morphology not relevant.
Marrow CR is defined as bone marrow = 5% myeloblasts and decrease by = 50% over pretreatment, stable disease with any hematological improvement, peripheral blood: if hematological improvement responses, they were noted in addition to marrow CR.
Stable Disease: Failure to achieve at least PR, but no evidence of progression for > 8 weeks.
Percentages were rounded off.
From randomization up to 31.01 months
Secondary Duration of Response (DOR) DOR is measured from time measurement criteria are first met for objective response to first date of relapse, disease progression (PD) /death, whichever occurs earlier.
Disease progression and relapse have been defined in outcome measure number 3. KM estimates were used for analysis.
From randomization up to 31.01 months
Secondary Red Blood Cell (RBC) Transfusion Independence Rate RBC transfusion independence rate is defined as the percentage of participants who have a 56-day or longer period with no RBC transfusions at any time between randomization and initiation of any new anticancer therapy, including SCT, among all participants who were RBC transfusion-dependent at Baseline. Percentages were rounded off. From randomization up to 31.01 months
Secondary Event Free Survival (EFS) EFS is defined as the time from randomization to transformation to acute myeloid leukemia (AML) or death from any cause, whichever occurs first.
Transformation assessments and deaths post SCT were included in the analysis. KM estimates were used for analysis
From randomization up to 31.01 months
Secondary Percentage of Participants With CR Rate in Participants With TP53 Mutation CR in TP53 mutant population is defined as the percentage of participants who achieve a morphologic CR based on investigator assessments using IWG criteria on or prior to initiation of any new anticancer therapy, including SCT in TP53 mutant population. Percentages were rounded off. From randomization up to 31.01 months
Secondary Minimal Residual Disease (MRD)-Negative Response Rate The MRD-negative response rate is defined as the percentage of participants who achieved a morphologic CR or marrow CR based on Investigator-assessed IWG criteria and reached MRD-negative disease status prior to initiation of any new anticancer therapy, including SCT. MRD-negative disease status was assessed using a multiparameter flow cytometry-based assay performed by a central laboratory. Transformation assessments post SCT were to be included in the analysis.
Morphologic CR and marrow CR are defined in outcome measures 1 and 4, respectively.
Percentages were rounded off.
From randomization up to 31.01 months
Secondary Time to Transformation to AML Time to transformation to AML is defined as the time from randomization to the collection date of bone marrow sample leading to documented AML diagnosis. KM estimates were used for analysis. From randomization up to 31.01 months
Secondary Progression Free Survival (PFS) PFS is defined as the time from randomization to the date of documented DP (including treatment failure by IWG criteria or relapse after PR/CR), or death from any cause, whichever occurs first. Response assessments and deaths post SCT were included in the analysis.
CR, PR and PD are defined in outcome measures 1, 4 and 5 respectively. KM estimates were used for analysis.
From randomization up to 31.01 months
Secondary Functional Assessment of Cancer Therapy-Anemia (FACT-Anemia) Response Rate The FACT-Anemia response rate is defined as the percentage of participants who showed clinically meaningful improvement in health-related quality of life (HRQoL) based on the score from the FACT-Anemia instrument prior to initiation of any new anticancer therapy, including SCT. The minimal clinically meaningful difference of 7.0 was used as cutoff for clinically meaningful improvement.
The FACT-Anemia instrument consists of 5 subscales, including physical well-being, emotional well-being, functional well-being, social well-being, and anemia symptoms. Each subscale measures items on a 5-point Likert scale from 0 to 4, where 0 = not at all and 4 = very much. The subscales are scored by summing points from all questions, then converting this sum to a 100 point scale; 0 indicates the poorest quality of life (QOL) and 100 denotes the highest QOL.
Percentages were rounded off.
Up to week 136
Secondary Percentage of Participants Experiencing Treatment-Emergent Adverse Events Treatment-emergent adverse events (TEAEs) are defined as any AEs with an onset date on or after the study drug start date and no later than 70 days after the study drug last dose date or the day before initiation of new anticancer therapy including SCT (whichever is earlier). If the AE onset date is on or before the last dose date, the AE is considered as TEAE regardless of the start of new anticancer therapy.
An AE is any unfavorable and unintended sign, symptom, or disease temporally associated with the use of an investigational product or other protocol imposed intervention, regardless of attribution.
An event is considered "serious", if it results in any of the following outcomes: death, life-threatening, inpatient or prolongation of existing hospitalization, persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, a congenital anomaly/birth defect, and important medical events.
First dose date up to 135.9 weeks plus 70 days (Up to 2.8 years)
Secondary Serum Concentration of Magrolimab Pretreatment assessments for the initial dose may be collected up to 72 hours before administration of study treatment; thereafter, pretreatment assessments are to be collected within 24 hours prior to study treatment administration. Preinfusion on Days 0, 7, 28, 56, 112, 168, 252 and 336
Secondary Percentage of Participants With Positive Anti-magrolimab Antibodies Percentages were rounded off. Up to 72 hours before administration of any treatment at Day 1, Cycle 1; within 24 hours prior to any study drug administration at Day 1 of Cycles 2, 3, 5, 7, 10, and 13 and End of Treatment (± 7 Days after last study drug dose); Cycle length is 28 Days
See also
  Status Clinical Trial Phase
Recruiting NCT05400122 - Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer Phase 1
Recruiting NCT05088356 - Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft Phase 1
Recruiting NCT04003220 - Idiopathic Chronic Thrombocytopenia of Undetermined Significance : Pathogenesis and Biomarker
Completed NCT02916979 - Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG Phase 1
Active, not recruiting NCT03755414 - Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation Phase 1
Completed NCT00003270 - Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer Phase 2
Recruiting NCT04904588 - HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide Phase 2
Terminated NCT04866056 - Jaktinib and Azacitidine In Treating Patients With MDS With MF or MDS/MPN With MF. Phase 1/Phase 2
Recruiting NCT04701229 - Haploinsufficiency of the RBM22 and SLU7 Genes in Del(5q) Myelodysplastic Syndromes
Suspended NCT04485065 - Safety and Efficacy of IBI188 With Azacitidine in Subjects With Newly Diagnosed Higher Risk MDS Phase 1
Recruiting NCT04174547 - An European Platform for Translational Research in Myelodysplastic Syndromes
Enrolling by invitation NCT04093570 - A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose), With a Food Effect Substudy at Select Study Centers Phase 2
Completed NCT02508870 - A Study of Atezolizumab Administered Alone or in Combination With Azacitidine in Participants With Myelodysplastic Syndromes Phase 1
Completed NCT04543305 - A Study of PRT1419 in Patients With Relapsed/Refractory Hematologic Malignancies Phase 1
Recruiting NCT05384691 - Efficacy of Luspatercept in ESA-naive LR-MDS Patients With or Without Ring Sideroblasts Who do Not Require Transfusions Phase 2
Recruiting NCT05365035 - A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts Phase 2
Recruiting NCT06008405 - Clinical Trial Evaluating the Safety of the TQB2928 Injection Combination Therapy Phase 1
Not yet recruiting NCT05969821 - Clonal Hematopoiesis of Immunological Significance
Withdrawn NCT05170828 - Cryopreserved MMUD BM With PTCy for Hematologic Malignancies Phase 1
Completed NCT02909972 - Safety Study of ALRN-6924 in Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome Phase 1

External Links